PROVAYBLUE (methylene blue) injection – original approved labeling (2016), including the accelerated-approval clause (2016)

Government Record · American Regent, Inc.; U.S. Food and Drug Administration · April 2016

American Regent et al., 2016-04: The 2016 original label approved ProvayBlue for acquired methemoglobinemia under accelerated approval, with continued approval contingent on verification of clinical benefit in later trials.

This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.

1

American Regent et al., 2016-04: The 2016 original label approved ProvayBlue for acquired methemoglobinemia under accelerated approval, with continued approval contingent on verification of clinical benefit in later trials. C1. Important qualification: the 2016 indication carried 'This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials. (1, 14)'. The string 'accelerated' appears twice in this 2016 label and zero times in the 2024 corrected label and in the current 2025 SPL, consistent with the 2024 efficacy supplement (SUPPL 21, approved 2024-01-08) converting or updating the application. Bearing PARTLY SUPPORTS because the label-supported status in 2016 was conditional. Note: this 2016 PDF carries the FDA banner that it may not be the latest approved labeling. Study type: regulatory record.